描述
Cell and Gene Therapy
CAR-T Testing Solutions
AR-T and NK cell therapies are among the most clinically advanced and commercially mature forms of cell therapy. Xuzhenda Biotech has extensive experience in CAR vector copy number analysis, lentiviral vector integration site analysis, and on-target/off-target assessment for gene editing. Backed by extensive project experience and well-established service workflows, we provide comprehensive analytical solutions for immune cell therapy development.To support the development of next-generation cell therapies, we also offer customized services, including single-cell vector copy number analysis, cytokine and immune biomarker profiling, and single-cell phenotypic and gene expression analysis. Our analytical solutions are designed to meet the quality requirements for clinical trials and regulatory submissions.We have collaborated with leading industry partners on multiple investigator-initiated trials (IITs) and registrational clinical studies, supported numerous IND and NDA submissions, and completed testing for thousands of clinical samples.
CAR-T/NK Solutions
描述
描述
Vector Sequence Integrity

Plasmid sequence release testing

Viral vector sequence release testing

Sanger / NGS / ONT sequencing

Allogeneic Donor Safety

Genome stability

HLA typing

STR profiling

Microbial contamination testing

Gene Modification Safety

Vector integration site analysis

CAR copy number determination

Gene editing efficiency

Off-target analysis

Cell Population Characterization

Gene expression profiling and functional analysis

Cell subset identification and classification

Immune profiling and clonotype tracking

Impurity cell detection

Immune Biomarkers

Cytokine profiling

Inflammatory immune response assessment

Long-term Follow-up

Long-term patient follow-up

In Vivo Cell Tracking

In vivo biodistribution tracking

Safety & Efficacy Biomarkers

Cytokine release syndrome (CRS) and neurotoxicity monitoring

Predictive biomarkers of therapeutic response

Prognostic Biomarkers

Mutation analysis

ctDNA analysis

MRD monitoring

Project Experience
  • 3 BLA/NDA Project
    autologous CAR-T
  • 15 Drug Phase I/II/III Clinical Trials
    autologous CAR-T
  • 30+ IND/IIT Project
    Autologous CAR-T, allogeneic universal CAR-T(CRISPR editing), in vivo CAR-T, autologous HSC (CRISPR editing), autologous HSC (base editing), TIL,mDAP (iPSC derived), MSC, mRNA tumor vaccine, siRNA, gene therapy (base editing), AAV
Advantages
Analysis of Genomic Insertion Sites of Integrated Vector
A mature, extensively validated detection workflow and a comprehensive analysis report covering genomic distribution of integration sites, integration site sequence preference analysis, enrichment analysis of tumor-associated gene insertion sites, and other key metrics. In addition to lentiviral vectors, this solution is also applicable to transposon vectors and other genomic integration vectors.
 Highly Sensitive Multiplex Immune Profiling
The high-sensitivity proteomic profiling solution enables simultaneous detection of over 11,000 protein markers, covering key signaling pathways. Among these, the multiplex immune and inflammatory cytokine assay enables absolute quantification of 5, 30, 45, or 150 cytokines with sensitivity down to fg/mL levels. This solution supports preclinical pharmacology, pharmacodynamics, and toxicology studies in cellular and animal models, as well as immune marker profiling of clinical trial samples before and after treatment to evaluate drug efficacy and safety.
Multiplex Absolute Quantification of Cytokines
EotaxinMIP-1BG-CSFMIGIL-10sIL-17FIL-33MMP-1TNF-a
MCP-4MCP-3IP-10EGFIL-13IL-18IL-4MMP-12TRAIL
MIP-3βMCP-2I-TACFLT3LIL-15IL-1BIL-6LOX-1TWEAK
MCP-1M-CSFSDF-1aHGFIL-17AIL-2IL-7OSMTSLP
MIP-1αGM-CSFIL-8IFN-yIL-17CIL-27TNF-BTGF-aVEGF-A
Immunological Profiling and Clone Tracing
Comprehensively characterize immune cell diversity, clonal expansion dynamics, and V(D)J rearrangement profiles at both single-cell and population levels; identify and track changes in disease-associated clones across different treatment stages, evaluate immune reset effects, and investigate the mechanisms of action of immunotherapies. Xuzhenda provides a range of immune repertoire analysis solutions tailored to diverse clinical scenarios. The methodology has been rigorously validated, supported by extensive experience in clinical trial sample testing.
描述
描述
描述
 

Peripheral blood immune cell clones track tumor immune microenvironmentImmune response research, antibody screening TCR-T designPeripheral blood immune cell clones track tumor immune microenvironment
Technical route5’RACE5’RACEscRNA
ApplicationsPartial clinical purposeR&D or early development of therapiesResearch and development
Immunization bank coverage
Middle and highHighMedium to High
Sample typeFFPE in peripheral blood, lymphoid tissue, tumor tissuePBMC, enriched lymphocytes, mouse spleen, tumor tissuePBMC, enriched lymphocytes, mouse spleen, tumor tissue
Starting nucleic acid materialDNARNASingle-cell RNA
Target regionCDR3 regionCDR3 regionCDR3 region
Disease AreaSolid tumors, vaccine development, immunotherapySolid tumors, autoimmunity, immunodeficiency, infections, etc.Solid tumors, autoimmunity, immunodeficiency, infections, etc.
validation status

T-Track TCR (Validated)

BCR-DNA (Under Validation)

Takara TCR (Validated)

Takara TCR (Under Validation)

Under Validation